Podcast appearances and mentions of Roger S Mcintyre

This special episode of AJP Audio brings together the editors of the American Journal Psychiatry and the AJP Residents' Journal to discuss important and impactful articles published in 2025. 00:39   Ned H. Kalin, M.D., discusses "Transcriptomic Analysis of the Human Habenula in Schizophrenia" by Ege A. Yalcinbas, Ph.D., et al. 06:23   Elisabeth Binder, M.D., Ph.D., discusses "Copy Number Variant Architecture of Child Psychopathology and Cognitive Development in the ABCD Study" by Zhiqiang Sha, Ph.D., et al. 11:17   Kathleen T. Brady, M.D., Ph.D., discusses "High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies" by Stephanie Lake, Ph.D., et al. 15:35   David A. Lewis, M.D., discusses "20 Years of Aberrant Salience in Psychosis: What Have We Learned?" by Philip R. Corlett, Ph.D., and Kurt M. Fraser, Ph.D. 17:27   William M. McDonald, M.D., discusses "Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research" by Roger S. McIntyre, M.D., F.R.C.P.C., et al. 24:04   Daniel S. Pine, M.D., discusses "Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial" by Carlos M. Grilo, Ph.D., et al. 26:06   Carolyn Rodriguez, M.D., Ph.D., discusses "Randomized Controlled Trial of the Effects of High-Dose Ondansetron on Clinical Symptoms and Brain Connectivity in Obsessive-Compulsive and Tic Disorders" by Emily R. Stern, Ph.D., et al. 30:26   Sean T. Lynch, M.D., discusses "From Medical Practice to Mass Incarceration: A Historical Analysis of Racial and Ethnic Targeting in U.S. Drug Policy" by Rathisha Pathmathasan, D.O., et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org  

What were some new treatments approved by the FDA? What did we learn about the long-term safety of methylphenidate in childhood ADHD? Are there benefits to long-term maintenance treatment with antidepressants in bipolar disorder? What did we learn about the safety and efficacy of subcutaneous racemic ketamine for treatment-resistant depression and MDMA for PTSD? In this episode, Dr. Andrew Cutler and Dr. Roger McIntyre address these questions and so much more about this past year in psychopharmacology.   Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His work broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.    

In this episode, we take a look back at Dr. Roger McIntyre's presentation on the treatment spectrum for depression and mania. In this sneak peek, Dr. McIntyre focuses on the current treatments that are available for the bipolar disorder spectrum. He addresses the implications of comorbid substance abuse with respect to pharmacological treatments. He also discusses lifestyle factors that can be preventative against cognitive decline associated with mood disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World's Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

What unique risk factors surround the COVID-19 pandemic and potential heightened risk of suicide? What populations have been most vulnerable to mental health consequences, substance use disorders, suicidal ideation, and self-harm during the pandemic and why? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on the suicide risk and prevalence during this challenging time. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

What is the evidence that obesity leaves one vulnerable to bipolar disorder? Which of your patients with bipolar disorder would you refer for TMS and what has been the outcome in your experience? Have you seen development of mania with this treatment? What impact or changes have you seen in your bipolar patients who have suffered with COVID? In this Bonus episode of the NEI Podcast, Dr. Roger McIntyre addresses these questions and more unanswered questions from the Q&A session for our NEI Synapse Half-Day on The Cutting-Edge of Mood Disorders. Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders. To register for Synapse Half-Days go to: https://www.neiglobal.com/Synapse/SynOverview/tabid/468/Default.aspx

What do clinicians need to know about the pharmacokinetics of ketamine, especially when it comes to drug-drug interactions? What is the abuse potential for ketamine and for esketamine? What are some ways that clinicians can mitigate the risk of abuse? At this time, what is the consensus, in comparing the efficacy of ketamine and esketamine for treatment resistant depression? In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre and Dr. Stephen Stahl on their recent publication in the American Journal of Psychiatry. To access the article click on the link: https://pubmed.ncbi.nlm.nih.gov/33726522/ Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. The second theme is treatment-resistant depression and suicide prevention. Episodes to be released under this theme include: Part 1: Treatment Resistant Depression and Suicide Prevention: Hot Off the Press Ketamine Guidelines with Dr. Roger McIntyre Part 2: Shelter-In-Place During the Storm: Mental Health Consequences and Suicide Prevention During the COVID-19 Pandemic with Dr. Roger McIntyre Part 3: Beyond the Storm: An Update on Suicide Prevention and The Suicide Prevention Handbook with Dr. Christine Moutier Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this webinar, psychiatrist Roger S. McIntyre discusses with Senior Medical Science Liaison Kimberly Lonergan the psychological impact of COVID-19 on those with and without psychiatric illnesses. Dr. McIntyre speaks of the “triple threat” posed by the pandemic. There is the biomedical threat, which sparks anxiety about the health of oneself as well as about that of loved ones. There is the economic uncertainty it has created for many, with employment lost and possible recession looming. And then there is physical distancing, which can increase feelings of isolation and loneliness. This webinar covers the mental health status of individuals during the pandemic, the impact of social media, and rises in suicide rates, which are sensitive to macroeconomic conditions. Dr. McIntyre closes the webinar by offering helpful resources. Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.

Guest: Roger S. McIntyre, MD, FRCPC Approximately a quarter of patients with depression in a primary care setting may actually have bipolar disorder.1 A significant number of patients with bipolar disorder are receiving a misdiagnosis of unipolar depression.2 The consequences of misdiagnosis can be substantial.3 It’s critical for primary care providers to stay alert for historical and emerging symptoms of bipolar disorder in undiagnosed patients, gain expertise in providing ongoing treatment to diagnosed patients, and know how to manage comorbidities, explains Dr. Roger McIntyre Professor of Psychiatry and Pharmacology at the University of Toronto, in an article entitled, Bipolar Depression: The Clinical Characteristics and Unmet Needs of a Complex Disorder. The open access article is available online at the journal’s website: Roger S. McIntyre & Joseph R. Calabrese (2019) Bipolar depression: the clinical characteristics and unmet needs of a complex disorder, Current Medical Research and Opinion, 35:11, 1993-2005, DOI: 10.1080/03007995.2019.1636017 References 1. Hirschfeld RMA, Cass AR, Holt DCL, et al. J Am Board Fam Pract. 2005;18(4):233-239. 2. Hirschfeld RMA, Lewis L, Vornik LA. J Clin Psychiatry. 2003; 64:161–174.3. Berk M, Hallam K, Lucas N, et al. Med J Aust. 2007;187:S11–4.

Host: Jennifer Caudle, DO Guest: Roger S. McIntyre, MD, FRCPC Nationally, approximately 43% of family physicians are providing mental health care, and approximately 25% of patients with depression in a primary care setting may actually have bipolar disorder.1,2 A possible cause of misdiagnosis is that depressive episodes are commonly the initial presentation of the disease.3 Faster recognition and more accurate management of patients with bipolar depression is absolutely critical, explains Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto, in an article entitled, Bipolar Depression: The Clinical Characteristics and Unmet Needs of a Complex Disorder. The open access article is available online at the journal’s website: Roger S. McIntyre & Joseph R. Calabrese (2019) Bipolar depression: the clinical characteristics and unmet needs of a complex disorder, Current Medical Research and Opinion, 35:11, 1993-2005, DOI: 10.1080/03007995.2019.1636017 References 1. Hirschfeld RMA, Cass AR, Holt DCL, et al. J Am Board Fam Pract. 2005;18(4):233-239. 2. Xierali IM, Tong ST, Petterson SM, et al. J Am Board Fam Pract. 2013;26(2):114-115. 3. Mitchell PB, Goodwin GM, Johnson GF, et al. Bipolar Disord. 2008;10:144–152.

Guest: Roger S. McIntyre, MD, FRCPC Approximately a quarter of patients with depression in a primary care setting may actually have bipolar disorder.1 A significant number of patients with bipolar disorder are receiving a misdiagnosis of unipolar depression.2 The consequences of misdiagnosis can be substantial.3 It’s critical for primary care providers to stay alert for historical and emerging symptoms of bipolar disorder in undiagnosed patients, gain expertise in providing ongoing treatment to diagnosed patients, and know how to manage comorbidities, explains Dr. Roger McIntyre Professor of Psychiatry and Pharmacology at the University of Toronto, in an article entitled, Bipolar Depression: The Clinical Characteristics and Unmet Needs of a Complex Disorder. The open access article is available online at the journal’s website: Roger S. McIntyre & Joseph R. Calabrese (2019) Bipolar depression: the clinical characteristics and unmet needs of a complex disorder, Current Medical Research and Opinion, 35:11, 1993-2005, DOI: 10.1080/03007995.2019.1636017 References 1. Hirschfeld RMA, Cass AR, Holt DCL, et al. J Am Board Fam Pract. 2005;18(4):233-239. 2. Hirschfeld RMA, Lewis L, Vornik LA. J Clin Psychiatry. 2003; 64:161–174.3. Berk M, Hallam K, Lucas N, et al. Med J Aust. 2007;187:S11–4.

Host: Jennifer Caudle, DO Guest: Roger S. McIntyre, MD, FRCPC Nationally, approximately 43% of family physicians are providing mental health care, and approximately 25% of patients with depression in a primary care setting may actually have bipolar disorder.1,2 A possible cause of misdiagnosis is that depressive episodes are commonly the initial presentation of the disease.3 Faster recognition and more accurate management of patients with bipolar depression is absolutely critical, explains Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto, in an article entitled, Bipolar Depression: The Clinical Characteristics and Unmet Needs of a Complex Disorder. The open access article is available online at the journal’s website: Roger S. McIntyre & Joseph R. Calabrese (2019) Bipolar depression: the clinical characteristics and unmet needs of a complex disorder, Current Medical Research and Opinion, 35:11, 1993-2005, DOI: 10.1080/03007995.2019.1636017 References 1. Hirschfeld RMA, Cass AR, Holt DCL, et al. J Am Board Fam Pract. 2005;18(4):233-239. 2. Xierali IM, Tong ST, Petterson SM, et al. J Am Board Fam Pract. 2013;26(2):114-115. 3. Mitchell PB, Goodwin GM, Johnson GF, et al. Bipolar Disord. 2008;10:144–152.

Roger S. McIntyre, MD, returns the Psychcast, this time to talk with host Lorenzo Norris, MD, about the mental health hazards of COVID-19 and what clinicians can do to help protect patients. Dr. McIntyre is professor of psychiatry and pharmacology, and head of the mood disorders psychopharmacology unit at the University Health Network at the University of Toronto. He disclosed receiving research or grants from the Stanley Medical Research Institute and the CIHR/GACD/National Natural Science Foundation of China. Dr. McIntyre also disclosed receiving consultation/speaker fees from several pharmaceutical companies. Dr. Norris has no disclosures.  Take-home points Uncertainty tied to the COVID-19 pandemic threatens to undermine mental health and exacerbate problems for those with mental illness. U.S. suicide rates, which were already rising after the Great Recession of 2007-2009, are likely to climb further because of the impact of COVID-19. Clinicians can take steps to prevent some of the negative mental health outcomes tied to the pandemic. Summary COVID-19 presents a triple threat to patients' mental health. The fear of viral infection is a mental health hazard. The financial shock that COVID-19 has had on the economy has not been seen since the Great Depression. Links between suicide and unemployment are powerful. In a study published in World Psychiatry, McIntyre and colleagues found associations between COVID-19 and major depression, PTSD, binge alcohol use, and substance use disorders. French social scientist Emile Durheim, PhD described the link between suicide and unemployment. Quarantining affects mental health, and there is nothing like COVID-19 in the history books. The Toronto experience with severe acute respiratory syndrome in 2003 offers lessons about the devastating impact of quarantining on mental health. “Deaths of despair” in the form of suicides have been on the increase in the United States. From the Great Recession, researchers found that for every 1% increase in unemployment, there is a commensurate 1% increase in suicide. U.S. unemployment stood at 8%-9% during the Great Recession, and now those percentages are much higher. Dr. McIntyre and his team projected that an unemployment rate of 14%-20% would lead to an additional 8,000-10,000 suicides could occur each year for the next 2 years. That’s in addition to the current number of approximately 50,000 suicides annually. Express Scripts, a pharmacy benefits manager, recently reported a 40% increase in prescriptions for anxiety-related medications. This suggests that people are distressed. Clinicians should take an aspirational approach to addressing these issues by pivoting to virtual platforms to increase patients’ access to care. Create medical homes that are HIPAA compliant. Look toward evidence-based models such as those found in Japan. That country found that, for every 0.2% increase in GDP spending on mental health care right after the Great Recession, the suicide rate fell by 1%. Encourage patients to structure the day and avoid consuming too much news or participating on social media. Two studies conducted in China found that people who spent more than 2-3 hours a day on news consumption were more likely to report clinical levels of depression, anxiety, and insomnia. Social media consumption has been associated with many adverse mental health outcomes, including loneliness. People who spent more than 3 hours a day were more likely to experience depression. Support programs for small-business people; jobs enhance resilience. Target the “basics” of self-care, such as getting enough sleep and engaging with others. References McIntyre RS, Lee Y. Psychiatry Res. 2020 May 19. doi: 10.1016/j.psychres.2020.113104. McIntyre RS, Lee Y. World Psychiatry. 2020 Jun;19(2):250-1. Shanahan L et al. Am J Public Health. 2012 Jun;109(6):854-8. Kang S, Chua HC. CMAJ. 2004 Mar 2;170(5):811-2. Express Scripts. America’s State of Mind Report. 2020 Apr 16. Lee Y et al. Psychiatry Clin Neurosci. 2020 Jul 1. doi: 10.1111/pch.13101. Hao F et al. Brain Behav Immun. 2020 Jul;87:100-6. Tan W et al. Brain Behav Immun. 2020 Jul;87:84-92. Wang C et al. Brain Behav Immun. 2020 Jul;87:40-8. Harvey SB et al. Am J Psychiatry. 2018 Jan 1;175(1):28-36. *  *  * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com

The Scott Thompson Show The charges against Derek Chauvin were upgraded, and the four other officers involved are now charged with aiding and abetting second-degree murder and aiding and abetting second-degree manslaughter. Guest: Reggie Cecchini, Washington Producer and Correspondent with Global News - How can we help fight against racism in our own community. Mouna Bile is with the Hamilton Community Legal Clinic and joins Scott to discuss ways we can address racism. Guest: Mouna Bile, bilingual black justice coordinator, Hamilton Community Legal Clinic - One of the suggestions from local activists is to defund the police, divert money into other initiatives that benefit communities. What does “defunding” mean, exactly, and how would a community like Hamilton go about the process? Guest: Ryan McGreal, Editor of Raise the Hammer - A new study from the University of Toronto suggests that economic upheaval and other issues surrounding the COVID-19 pandemic could result in a spike of suicide deaths. How can we manage mental health during the pandemic? Guest: Roger S. McIntyre, M.D., FRCPC  Professor of Psychiatry and Pharmacology, University of Toronto, Canada

Neurocognitive deficits are commonly experienced by individuals living with bipolar disorder. Bipolar disorder is known to affect attention, processing speed, verbal learning and memory, and executive functions, including working memory and verbal fluency. During this webinar, Dr. Roger S. McIntyre discusses cognitive dysfunction in adults with bipolar disorder and associated health implications; underlying mechanisms that may contribute to cognitive dysfunction; and the importance of preserving cognitive function in this population. Roger S. McIntyre, M.D., FRCPC, is a Professor of Psychiatry & Pharmacology at the University of Toronto. He also serves as Head of the Mood Disorders Psychopharmacology Unit University Health Network, and Executive Director of the Brain & Cognition Discovery Foundation. He received his medical degree at Dalhousie University and completed his psychiatry residency at the University of Toronto. Disclaimers Speaker is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC. MRC2.CORP.X.03556 / MRC2.CORP.X.03556

You won't want to miss this episode! Chairman, Dr. Roger S. McIntyre highlights what's to come over the next few days. You'll hear about a change in our format, and some of the most exciting topics to date! Our team is in Asheville, NC putting final touches on the 2019 NEI Synapse experience! We're eager to welcome our attendees and share the tips, tools, and knowledge that we've been cultivating for the past year. 

On this week’s episode of The Super Awesome Science Show, we dig into the nature of the ketogenic diet, its history, and what good it can do for you. There are all sorts of diets but only a few have proven to be effective at helping you lose weight. One of the most popular options that also works is the ketogenic diet. It’s known as a fat buster as it helps to melt away unwanted fat while improving your metabolic health.      We first start with Desiree Nielsen, a registered dietitian, author, and television host. She helps us understand what the ketogenic diet does to our bodies and how best to find the right foods to improve your chances at losing weight. My next guest is Dr. Roger McIntyre at the University of Toronto. He explains that there’s a potential hidden benefit of choosing the keto diet. It may help you emotionally and maintain your mental health. Although as he says, this isn’t quite ready for prime time, you’ll want to hear how the latest research may one day help us to stay balanced naturally. In our SASS class, we pour a little cold water on the keto diet by finding out just how much weight we can expect to lose and how long the diet will keep burning the fat. The Knowledge Translation and Evidence Coordinator for the College of Family Physicians, Adrienne Lindblad tells us that when it comes to weight loss, the keto diet may not be your first choice. If you enjoy The Super Awesome Science Show, please take a minute to rate it on Apple Podcasts and be sure to tell a friend about the show. Thanks to you, we’ve been nominated for a Canadian Podcast Award as Outstanding Science and Medicine Series. Let’s keep the awesome momentum going together!   Twitter: @JATetro Email: thegermguy@gmail.com Guests: Desiree Nielsen Registered Dietitian https://desireerd.com/ Twitter: @desireerd Dr. Roger S. McIntyre University of Toronto https://www.uhnresearch.ca/researcher/roger-s-mcintyre Adrienne Lindblad College of Family Physicians http://peerevidence.ca/the-team/adrienne-lindblad/ Twitter: @ajlindblad

In this episode we share Dr. Roger McIntyre's perspective on central themes that underlie mental health conditions, which he shared with us this past year at Synapse in Las Vegas. Find out what homeostasis and hedonism might mean for you in terms of treating patients!  Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.